www.fgks.org   »   [go: up one dir, main page]
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;14(9):1241-53.
doi: 10.1586/14760584.2015.1073110. Epub 2015 Jul 29.

Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations

Negar Aliabadi  1 , Ben A Lopman, Umesh D Parashar, Aron J Hall
Affiliations
Free PMC article
Review

Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations

Negar Aliabadi et al. Expert Rev Vaccines. 2015.
Free PMC article

Abstract

Human norovirus infection causes significant medical and financial costs in the USA and abroad. Some populations, including young children, the elderly, and the immunocompromised, are at heightened risk of infection with this virus and subsequent complications, while others, such as healthcare workers and food handlers are at increased risk of transmitting it, and some are at risk of both. Human noroviruses are heterogeneous with new strains emerging periodically. In addition to viral diversity, incompletely understood characteristics, such as virus-host cell binding and duration of immunity after infection add to the challenges of creating a norovirus vaccine. Although much progress has been made in recent years, many questions remain to be answered. In this review, we discuss the important areas and relevant literature in considering human norovirus vaccine development and potential targets for implementation.

Keywords: Norwalk agent; calciviridae; epidemiology; gastroenteritis; norovirus; vaccine development.

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

No writing assistance was utilized in the production of this manuscript.

Similar articles

  • Norovirus vaccine development: next steps.
    Atmar RL, Estes MK. Atmar RL, et al. Expert Rev Vaccines. 2012 Sep;11(9):1023-5. doi: 10.1586/erv.12.78. Expert Rev Vaccines. 2012. PMID: 23151158 Free PMC article. No abstract available.
  • Human noroviruses: recent advances in a 50-year history.
    Atmar RL, Ramani S, Estes MK. Atmar RL, et al. Curr Opin Infect Dis. 2018 Oct;31(5):422-432. doi: 10.1097/QCO.0000000000000476. Curr Opin Infect Dis. 2018. PMID: 30102614 Review.
  • New insights into the global burden of noroviruses and opportunities for prevention.
    Hall AJ, Glass RI, Parashar UD. Hall AJ, et al. Expert Rev Vaccines. 2016 Aug;15(8):949-51. doi: 10.1080/14760584.2016.1178069. Epub 2016 May 3. Expert Rev Vaccines. 2016. PMID: 27142965 Free PMC article. No abstract available.
  • Norovirus.
    Robilotti E, Deresinski S, Pinsky BA. Robilotti E, et al. Clin Microbiol Rev. 2015 Jan;28(1):134-64. doi: 10.1128/CMR.00075-14. Clin Microbiol Rev. 2015. PMID: 25567225 Free PMC article. Review.
  • Vaccine against norovirus.
    Tan M, Jiang X. Tan M, et al. Hum Vaccin Immunother. 2014;10(6):1449-56. doi: 10.4161/hv.28626. Epub 2014 May 5. Hum Vaccin Immunother. 2014. PMID: 24718366 Free PMC article. Review.
See all similar articles

Cited by 18 articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources